Verona Pharma plc Verona Pharma Completes Enrollment In Phase 2 Clinical Trial Evaluating Nebulized Rpl554 As Add-on To Dual ...
31 October 2018 - 6:00PM
UK Regulatory
TIDMVRP
Enrollment complete ahead of schedule
Top line data expected in January 2019
LONDON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that is has enrolled the last
patient in its Phase 2 clinical trial evaluating the effect of nebulized
RPL554 as an add-on to dual therapy using long-acting anti-muscarinic /
long-acting beta2-agonists ("LAMA/LABA") and triple therapy (LAMA/LABA
with an inhaled corticosteroid) in the maintenance treatment of patients
with moderate to severe chronic obstructive pulmonary disease ("COPD").
A total of 79 patients with COPD have enrolled at sites in the U.S. and
in the UK in this three way crossover study. It is anticipated that it
will take several weeks to complete dosing. Following data analysis, top
line data is expected to be available in January 2019.
This randomized, double-blind, three-way crossover trial is designed to
investigate the efficacy and safety of nebulized RPL554 as an add-on to
an inhaled LAMA/LABA, tiotropium/olodaterol (Stiolto(R) Respimat(R) ),
compared to placebo. Those patients already receiving inhaled
corticosteroid ("ICS") anti-inflammatory therapy will continue a stable
dose of ICS throughout the study, thus providing additional data on
"triple therapy" use. Following a 7- to 14-day washout period in advance
of dosing and between study arms, patients will receive three days of
treatment with each of two dose strengths (1.5 mg or 6.0 mg) of
nebulized RPL554 or placebo twice daily. The primary endpoint of this
trial is improvement in lung function with RPL554 vs placebo (as add-on
to tiotropium/olodaterol), as measured by peak forced expired volume in
one second (FEV(1) )(,) a standard measure of exhaled breath volume to
evaluate respiratory function.
"We are delighted that enrollment in this Phase 2 study has been
completed ahead of schedule and now expect to report top line data in
January following completion of dosing and data analysis," stated
Jan-Anders Karlsson, PhD, CEO of Verona Pharma, "We have already
demonstrated that RPL554, when administered as an add-on to a single
bronchodilator, produces a large and sustained improvement in lung
function. This study is expected to further inform the positioning of
RPL554 as an add-on to dual bronchodilator therapy (with some patients
also on inhaled corticosteroid as background treatment) for the
treatment of more severe COPD patients, who continue to experience
disease progression and worsening of symptoms despite being treated with
currently available COPD therapies."
RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 designed to have bronchodilator as well as
anti-inflammatory properties, and is currently in development for the
maintenance treatment of COPD and for the treatment of cystic fibrosis
("CF").
About COPD
Chronic obstructive pulmonary disease ("COPD") is a progressive and
life-threatening respiratory disease for which there is no cure.(1)
Although COPD is thought to be underdiagnosed, globally, around 384
million people suffer from the disease.(2) This number, according to the
World Health Organization ("WHO"), is likely to increase in coming years,
with estimates that COPD will become the third leading cause of death
worldwide by 2030.(1,3) The condition damages the airways and the lungs,
leading to persistent symptoms of breathlessness, impacting a person's
daily life and their ability to perform simple activities such as
walking a short flight of stairs or carrying a suitcase.(1) Many
experience acute periods of worsening symptoms called 'exacerbations',
often leading to emergency department visits or hospital admissions and
are also associated with high mortality.(4) In the United States alone,
the 2010 total annual medical costs related to COPD were estimated to be
$32 billion and are projected to rise to $49 billion in 2020.(5) About
30-40% of moderate to severe COPD patients on triple inhaled therapy
(ICS/LAMA/LABA) remain uncontrolled and continue to experience airway
obstruction (breathing difficulties), COPD symptoms and
exacerbations.(6) There is an urgent need for drugs with novel
mechanisms of action that can be used by these patients in addition to
current therapies.
About Verona Pharma plc and RPL554
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a
bronchodilator and an anti-inflammatory agent in a single compound. In
previous clinical trials, RPL554 has been observed to result in
bronchodilator effects when used alone or as an add-on treatment to
other COPD bronchodilators. It has shown clinically meaningful and
statistically significant improvements in lung function when
administered in addition to frequently used short- and long-acting
bronchodilators, such as tiotropium (Spiriva(R)), compared with such
bronchodilators administered as a single agent. RPL554 improved FEV(1)
over four weeks in patients with moderate-to-severe COPD when compared
to placebo and improved COPD symptoms and Quality of Life in a Phase 2b
multicenter European study performed in 403 patients. In addition,
RPL554 has shown anti-inflammatory effects in a standard challenge study
with COPD-like inflammation in human subjects. RPL554 has been well
tolerated in these studies and has a favorable safety and tolerability
profile, having been administered to more than 730 subjects in 12
clinical trials. Verona Pharma is developing RPL554 for the treatment of
chronic obstructive pulmonary disease ("COPD"), cystic fibrosis ("CF"),
and potentially asthma.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, but not limited to, statements regarding the design of the
Phase 2 clinical trial of RPL554, the timing of availability of top-line
data for the Phase 2 clinical trial, the importance of the Phase 2
clinical trial to our development plans for RPL554, the potential of
RPL554 as a promising first-in-class treatment option for COPD, and the
value of the data and insights that may be gathered from the Phase 2
clinical trial, including for the purpose of designing pivotal Phase 3
trials.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of RPL554, which
may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of RPL554, our only product candidate under
development; economic, political, regulatory and other risks involved
with international operations; the lengthy and expensive process of
clinical drug development, which has an uncertain outcome; serious
adverse, undesirable or unacceptable side effects associated with
RPL554, which could adversely affect our ability to develop or
commercialize RPL554; potential delays in enrolling patients, which
could adversely affect our research and development efforts and the
completion of our Phase 2 trial; we may not be successful in developing
RPL554 for multiple indications; our ability to obtain regulatory
approvals necessary to conduct later stage trials and to commercialize
RPL554 in multiple major pharmaceutical markets; misconduct or other
improper activities by our employees, consultants, principal
investigators, and third-party service providers; material differences
between our "top-line" data and final data; our reliance on third
parties, including clinical investigators, manufacturers and suppliers,
and the risks related to these parties' ability to successfully develop
and commercialize RPL554; and lawsuits related to patents covering
RPL554 and the potential for our patents to be found invalid or
unenforceable. These and other important factors under the caption "Risk
Factors" in our Annual Report on Form 20-F filed with the Securities and
Exchange Commission ("SEC") on February 27, 2018 relating to our
Registration Statement on Form F-1, and our other reports filed with the
SEC, could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press release.
Any such forward-looking statements represent management's estimates as
of the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283
4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20
and UK Broker) 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727
1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
(1) World Health Organization. Chronic Obstructive Pulmonary Disease.
https://www.globenewswire.com/Tracker?data=_mJ4LFAN-wsgi0B2x_9YdY0fiDpP-BfTGyTqYp6dbHM8C0ZdGrzMqhXE12-z7P7vfC44AXcJuSYMeN_ePDBOHVLkuxPWzIFniVf_xgFvs65esbAE7iFy3EqTAm-YuXgHHq1CXq-ahyK3iOLikV7VLA5CIx0Etggmq8b03Fo11Zc=
http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed September
2017.
(2) Adeloye D, Chua S, et al. Global and regional estimates of COPD
prevalence: Systematic review and meta-analysis. J Glob Health 2015;
5(2): 020415.
(3) World Health Organization. Burden of COPD.
https://www.globenewswire.com/Tracker?data=_mJ4LFAN-wsgi0B2x_9YdSFzDtaYhaVSIc6xZlGqnQtpEHir-oLUUB0f9C0febKh6QtKiQhOj4nnGzWTEHDgLJ1mEpBmwLws0_7KNc2CVJSkIAF3LWS8kXaC-vyvZzCqZeyrlq-Q3Bhu_TaIy_gAwsE2IJn3ICMRTJvrvAk-cv4=
http://www.who.int/respiratory/copd/burden/en/. Accessed September 2017.
(4) COPD Foundations. Characteristics of COPD Patients Using United
States Emergency Care or Hospitalization.
https://www.globenewswire.com/Tracker?data=MAX7LGQvvvXy01yeVS6j8ZCJQY_xQg1_KCj-wUhyHrV3Vnkn0t2skvObDfraHag-C0xCPpbsBUzTDZu7ePA7QSvuOPi3vOK9O5ANvrzxrZMjzo9r1EsMDiRKWetoVbeKBuOtACbrOdb67nbyxD5fQ3I85o9ZMzCucntN15bgEAyrSl5iJi1yHFtgXzNU6Nfp_1eAmB95Djm7I__47tMTjW3rxthgGhm-KDwboqHNP72DW1RaCyf6gH9zH_zEmfOCIbtKcHN1ONWy53GXem95S_zi-b_JEVwc8JrHpb6N6bfDvXJZuODAuILkS7x3KLKIX1knhBmoHSnzKMSWV3D-blBjypZCGcl74uia3N4X0024mRDztMeZ4VKefnpIQYUNOZcIEbNxGwpc1Nfj_aQ8gw==
https://journal.copdfoundation.org/jcopdf/id/1103/Characteristics-of-COPD-Patients-Using-United-States-Emergency-Care-or-Hospitalization.
Accessed September 2017.
(5) Centers for Disease Control. Increase Expected in Medical Costs for
COPD.
https://www.globenewswire.com/Tracker?data=MAX7LGQvvvXy01yeVS6j8fjX4wuzkwlL2ksTTETXdvf5a1di7WVNAhuV76xkLlmfTMa4bUgQ_qrJ0PSMtwqDu6nMDLaFELfMQVYovmW-afSiY8D0xEEIsDW93cRtxWJcmDnd4EQg0Zs1ZBTbhgzbPw==
https://www.cdc.gov/features/ds-copd-costs/. Accessed September 2017.
(6) Mullerova H., et al., Characterization of COPD Patients Treated With
Inhaled Triple Therapy Containing Inhaled Corticosteroid [ICS],
Long-Acting Beta2-Agonists [LABA], and Long-Acting Muscarinic
Antagonists [LAMA] in the UK, American Journal of Respiratory and
Critical Care Medicine 2017;195:A4986
(6) Vestbo J, et al., Single inhaler extrafine triple therapy versus
long-acting muscarinic antagonist therapy for chronic obstructive
pulmonary disease (TRINTY); a double-blind, parallel group, randomised
controlled trial, The Lancet, Vol 389, p. 1919-1929; May 13, 2017.
(END) Dow Jones Newswires
October 31, 2018 03:00 ET (07:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024